FDA Updates Stribild Labeling

On August 28, 2014, FDA approved updates to the label for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir 300 mg) fixed-dose combination tablets. The label was updated with efficacy, resistance, and safety data from two clinical trials; renal information; and drug interaction information. The updated labeling for Stribild is available at the FDA website.  More information is available:  FDA: Press release AIDSinfo: Patient fact sheet on Stribild